Table 1 Patients characteristics
From: Comparison of two bone markers with growth evolution in 74 girls with central precocious puberty
Patients included | Patients excluded | MWU | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
value | n | Mean ± SD | Min | Max | % | n | Mean ± SD | Min | Max | p | ||
Age at onset (years) | 74 | 6.79 ± 1.18 | 3.00 | 8.00 | 419 | 6.66 ± 1.38 | 0.10 | 8.0 | 0.335 | |||
≤6 | 18 | 24.3 | ||||||||||
Initial evaluation | Age (years) | 74 | 7.50 ± 1.28 | 3.50 | 9.50 | 419 | 7.56 ± 1.47 | 0.75 | 10.58 | 0.479 | ||
BMI (kg/m2) | 74 | 17.40 ± 1.97 | 14.73 | 23.84 | 410 | 17.48 ± 2.20 | 12.21 | 25.45 | 0.673 | |||
BMI (SDS) | 74 | 0.1 ± 1.40 | −2.00 | 4.60 | 410 | 1.29 ± 1.59 | −2.4 | 6.6 | 0.958 | |||
≥2 | 7 | 9.4 | ||||||||||
Growth rate the year before (cm) | 70 | 7.55 ± 1.57 | 5.00 | 13.00 | 374 | 7.80 ± 2.17 | 2.00 | 24.00 | 0.593 | |||
Growth rate the year before (SDS) | 70 | 1.89 ± 1.80 | −1.1 | 6.6 | 374 | 2.32 ± 2.38 | −4.67 | 12.94 | 0.489 | |||
≥2 | 32 | 45.7 | ||||||||||
Height (cm) | 74 | 130.46 ± 9.57 | 101 | 146.5 | 419 | 130.63 ± 11.59 | 68.0 | 155.0 | 0.521 | |||
Height (SDS) | 74 | 2.06 ± 1.43 | −1.31 | 6.18 | 419 | 2.1 ± 1.3 | −2.9 | 5.3 | 0.913 | |||
Bone age (years) | 73 | 8.7 ± 1.6 | 4 | 11 | ||||||||
Difference between bone and chronological ages (years) | 73 | 1.23 ± 1.25 | −0.90 | 5.50 | 405 | 1.3 ± 1.3 | −2.5 | 6 | 0.787 | |||
≥2 | 24 | 32.9 | ||||||||||
Uterus length (mm) | 47 | 35.03 ± 8.02 | 21.00 | 58.00 | 223 | 36.19 ± 8.97 | 16.00 | 75.00 | 0.463 | |||
≥35 | 23 | 48.9 | ||||||||||
Basal LH concentration (IU/L) | 65 | 0.67 ± 0.83 | 0.10 | 5.00 | 334 | 0.84 ± 1.58 | 0.00 | 20.20 | 0.341 | |||
Basal FSH concentration (IU/L) | 64 | 2.04 ± 1.63 | 0.40 | 7.00 | 335 | 2.95 ± 2.09 | 0.20 | 10.00 | 0.001 | |||
LH peak (IU/L) | 74 | 8.95 ± 10.55 | 0.60 | 46.00 | 419 | 12.16 ± 14.90 | 0.20 | 101.0 | 0.059 | |||
FSH peak (IU/L) | 74 | 11.40 ± 5.96 | 0.80 | 36.50 | 419 | 12.84 ± 6.96 | 1.10 | 62.00 | 0.045 | |||
LH/FSH peak ratio | 74 | 0.96 ± 1.35 | 0.09 | 7.62 | 419 | 0.95 ± 1.07 | 0.04 | 9.83 | 0.170 | |||
≥0.66 | 27 | 36.5 | ||||||||||
Estradiol (pg/mL) | 74 | 13.4 ± 14.45 | 2.00 | 88.00 | ||||||||
≥15 | 20 | 27 | ||||||||||
BAP (μg/L) | 62 | 78.5 ± 30.3 | 32.1 | 167.2 | ||||||||
CTX (pg/L) | 69 | 5540 ± 6438.9 | 682 | 54,627 | ||||||||
Untreated patients | 49 | 66.2 | ||||||||||
Growth rate 6 months following initial evaluation (cm) | 28 | 3.8 ± 1.1 | 2 | 6 | ||||||||
Growth rate 6 months following initial evaluation (SDS) | 28 | 2 ± 2.5 | −2.25 | 8 | ||||||||
Growth rate the year following initial evaluation (cm) | 16 | 7.6 ± 1.8 | 4.7 | 11 | ||||||||
Growth rate the year following initial evaluation (SDS) | 16 | 2.1 ± 2.2 | −1.5 | 6.6 | ||||||||
≥2 | 8 | 50 | ||||||||||
Adult height (cm) | 21 | 163.7 ± 6.4 | 151 | 178 | ||||||||
Adult height (SDS) | 21 | 0.1 ± 1.1 | −2.2 | 2.6 | ||||||||
Difference between target and adult heights (cm) | 19 | −1.2 ± 3.7 | −7 | 4.5 | ||||||||
≥5 | 0 | 0 | ||||||||||